RBC Capital analyst Gregory Renza maintained a Buy rating on BELLUS Health (BLU – Research Report) on May 11 and set a price target of $14.00. The company's shares closed last Thursday at $7.81. According to TipRanks.com, Renza has 0 stars on 0-5 stars ranking scale with an average return of -10.1% and a 25.8% success rate. Renza covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Verrica Pharmaceuticals, and Pacira Pharmaceuticals. The word on The Street in general, suggests a Strong Buy analyst consensus rating for BELLUS Health with a $15.83 average price target, a 133.5% upside from current levels. In a report released yesterday, H.C.
https://www.tipranks.com/news/blurbs/rbc-capital-maintains-a-buy-rating-on-bellus-health-blu?utm_source=advfn.com&utm_medium=referral
Blue Chip Value Fund, Inc. (NYSE:BLU)
Historical Stock Chart
From Oct 2022 to Nov 2022 Click Here for more Blue Chip Value Fund, Inc. Charts.
Blue Chip Value Fund, Inc. (NYSE:BLU)
Historical Stock Chart
From Nov 2021 to Nov 2022 Click Here for more Blue Chip Value Fund, Inc. Charts.